“There’s no hidingthat investing in Neuren has its risks, that’s the nature of drug development, but external analystvaluations of the business today are multiples of the current share price with one at $3.93 and ourinternal modelling is higher again.”
Ann: AGM Chairman's Address and CEO Presentation, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.27 |
Change
0.640(3.85%) |
Mkt cap ! $2.177B | |||
| Open | High | Low | Value | Volume |
| $16.80 | $17.34 | $16.63 | $7.999M | 467.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3720 | $18.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.55 | 157 | 1 |
View Market Depth
| Last trade - 15.59pm 31/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |